Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.1434 EUR | -13.09% | -16.82% | -63.04% |
Mar. 20 | METabolic EXplorer: Noovistago on the road to reorganization | CF |
Mar. 12 | METabolic EXplorer: applies for safeguard proceedings | CF |
Valuation
Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
Capitalization 1 | 53.02 | 37.39 | 35.6 | 65.73 | 290.5 | 53 |
Enterprise Value (EV) 1 | 27.81 | 8.888 | 16.7 | 62.39 | 275.6 | 91.36 |
P/E ratio | -4.68 x | -6.16 x | -4.36 x | -7.29 x | 3.13 x | -1.04 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | 7.55 x | 6.69 x | 15.2 x | 34.6 x | 1.69 x | 0.23 x |
EV / Revenue | 3.96 x | 1.59 x | 7.15 x | 32.8 x | 1.61 x | 0.4 x |
EV / EBITDA | -3.03 x | -2.54 x | -2.54 x | -6.77 x | -26.6 x | -2.58 x |
EV / FCF | -2.11 x | -28 x | -0.99 x | -2.28 x | -4.18 x | -2.45 x |
FCF Yield | -47.4% | -3.58% | -101% | -43.8% | -23.9% | -40.8% |
Price to Book | 1.17 x | 0.94 x | 1.13 x | 2.23 x | 1.86 x | 0.51 x |
Nbr of stocks (in thousands) | 23,255 | 23,255 | 23,115 | 27,620 | 43,688 | 43,800 |
Reference price 2 | 2.280 | 1.608 | 1.540 | 2.380 | 6.650 | 1.210 |
Announcement Date | 4/30/18 | 4/30/19 | 2/29/20 | 4/29/21 | 4/29/22 | 4/28/23 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
Net sales 1 | 7.027 | 5.588 | 2.335 | 1.9 | 171.6 | 228.2 |
EBITDA 1 | -9.18 | -3.504 | -6.575 | -9.22 | -10.36 | -35.38 |
EBIT 1 | -10.85 | -5.03 | -8.377 | -10.78 | -14.34 | -42.92 |
Operating Margin | -154.35% | -90.01% | -358.76% | -567.26% | -8.35% | -18.81% |
Earnings before Tax (EBT) 1 | -11.31 | -5.226 | -8.51 | -9.725 | 73.49 | -47.85 |
Net income 1 | -11.27 | -6.093 | -8.245 | -8.932 | 84.12 | -50.83 |
Net margin | -160.41% | -109.04% | -353.1% | -470.11% | 49.03% | -22.28% |
EPS 2 | -0.4868 | -0.2609 | -0.3530 | -0.3267 | 2.125 | -1.160 |
Free Cash Flow 1 | -13.17 | -0.3178 | -16.81 | -27.35 | -65.93 | -37.32 |
FCF margin | -187.4% | -5.69% | -719.78% | -1,439.57% | -38.43% | -16.36% |
FCF Conversion (EBITDA) | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 4/30/18 | 4/30/19 | 2/29/20 | 4/29/21 | 4/29/22 | 4/28/23 |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2022 Q2 | 2022 S1 |
---|---|---|
Net sales 1 | 62.27 | 129.3 |
EBITDA | - | -7.4 |
EBIT | - | - |
Operating Margin | - | - |
Earnings before Tax (EBT) | - | - |
Net income | - | - |
Net margin | - | - |
EPS | - | - |
Dividend per Share | - | - |
Announcement Date | 9/30/22 | 9/30/22 |
Balance Sheet Analysis
Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | 38.4 |
Net Cash position 1 | 25.2 | 28.5 | 18.9 | 3.35 | 14.9 | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | -1.084 x |
Free Cash Flow 1 | -13.2 | -0.32 | -16.8 | -27.4 | -65.9 | -37.3 |
ROE (net income / shareholders' equity) | -22.2% | -13.7% | -18.8% | -21.1% | 80.8% | -39.6% |
ROA (Net income/ Total Assets) | -10% | -5.26% | -8.47% | -9.45% | -5.42% | -11.3% |
Assets 1 | 112.4 | 115.8 | 97.31 | 94.51 | -1,551 | 450.3 |
Book Value Per Share 2 | 1.950 | 1.700 | 1.360 | 1.070 | 3.580 | 2.380 |
Cash Flow per Share 2 | 1.350 | 1.520 | 1.150 | 0.6600 | 0.6300 | 0.3100 |
Capex 1 | 0.67 | 1.59 | 16.4 | 23.3 | 15.7 | 16 |
Capex / Sales | 9.49% | 28.4% | 703.13% | 1,227.11% | 9.14% | 7% |
Announcement Date | 4/30/18 | 4/30/19 | 2/29/20 | 4/29/21 | 4/29/22 | 4/28/23 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-63.04% | 8.94M | |
+2.80% | 103B | |
+1.20% | 67.05B | |
+44.29% | 40.4B | |
+15.99% | 38.64B | |
+3.89% | 32.41B | |
+6.82% | 19.17B | |
+12.32% | 16.76B | |
+17.69% | 15.07B | |
+8.31% | 14.82B |
- Stock Market
- Equities
- METEX Stock
- Financials METabolic EXplorer